Store lyophilized retatrutide sealed, desiccated, and dark: minus 20 °C or below for long holds, 2 to 8 °C for a working vial on a defined window. Let cold vials reach room temperature before opening, because condensation does more damage than most freezer settings prevent. A prepared solution is refrigerated, aliquoted, and dated.
- Retatrutide is Eli Lilly's LY3437943, a single 39-residue lipidated peptide engineered to activate the GIP, GLP-1, and glucagon receptors.
- Lyophilized retatrutide stores sealed, desiccated, and dark at minus 20 °C for long holds, and a cold vial must reach room temperature before it is opened.
- The C20 fatty diacid makes the molecule interface-active, so solutions are swirled gently and never shaken.
- Purity by RP-HPLC and net peptide content are different numbers, and a concentration calculated from the label without a content figure runs high.
- No approved medicine contained retatrutide as of 25 August 2026; the developer has stated plans to file with the FDA in the first quarter of 2027.
One molecule, three names
The compound sold as retatrutide is Eli Lilly's LY3437943, and a certificate of analysis may carry either name. Retatrutide is the international nonproprietary name. LY3437943 is the development code most of the primary literature uses. The class descriptor that follows it around, triple agonist, refers to engineered activity at three receptors: GIP, GLP-1, and glucagon. The research market's habit of shortening the name to reta is fine for conversation and useless on paperwork; a lot record should carry a name a database can find.
Structurally it is a single-chain peptide of 39 residues, engineered from the GIP sequence rather than stitched together from three separate hormones. The published preclinical characterization describes non-coded substitutions, including the α-aminoisobutyric acid this class relies on for resistance to enzymatic cleavage, a C20 fatty diacid conjugated through a linker to a lysine side chain, and an amidated C-terminus.
Two of those features decide how the material behaves on a bench. The fatty diacid makes the molecule amphiphilic, so it concentrates at air-water interfaces and can adsorb to container walls at low concentration, which is why the handling notes below keep returning to gentle swirling and minimal headspace. And the engineering that resists peptidases does nothing against water, oxygen, or heat. Cleavage resistance gets read as general toughness surprisingly often. It is no such thing, and a vial of retatrutide degrades by the same routes as any other lipidated peptide.
How to store the lyophilized powder
The query has a short answer. Keep the sealed powder cold, dark, and dry, and open it only at room temperature. Everything else on this page is detail on those conditions.
| State | Condition | Relative horizon | Why |
|---|---|---|---|
| Sealed powder, long-term hold | Minus 20 °C or below, desiccated, dark | Longest | Every degradation route is slowed and water is excluded |
| Sealed powder, working vial | 2 to 8 °C, dark | Weeks, on a defined window | Reasonable where the vial will be finished soon |
| Powder in transit | Ambient, insulated, dark | Days | A dry solid tolerates short excursions; a solution does not |
| Prepared solution | 2 to 8 °C, dark | Days | Hydrolysis and deamidation now have the water they need |
| Solution as single-use aliquots | Minus 20 °C or below | Longer, one thaw each | Freeze-thaw damage is cumulative and irreversible |
The ranking behind that table matters more than the table. Temperature changes the speed of every degradation route, which is why cold storage earns its place. Water is what most of those routes actually consume. A vial that stays dry at refrigerator temperature will generally outlast one held frozen and opened cold once a week, because opening a cold vial is how water gets in.
Glass at minus twenty sits far below the dew point of an ordinary room. Break the seal on a freezer-cold vial and humid air meets a cold, hygroscopic cake; the condensate lands, the cake takes it up, and the vial returns to the freezer wetter than it left. Nothing in the cake's appearance reports any of this. The control costs twenty to thirty minutes: let the sealed vial reach room temperature on the bench, work quickly once it is open, reseal against a desiccant, and log the excursion if the protocol tracks them. The degradation chemistry behind each of these rules, route by route, is laid out in the tirzepatide storage and stability guide; the same routes govern retatrutide, with the lipid chain making interfacial aggregation the one to respect most.
Once it is in solution
Adding water starts clocks that dry storage had stopped. Hydrolysis and deamidation begin at preparation, the lipid chain has an interface to work, and any organism introduced with the first draw has a medium to grow in. From that moment the storage question is measured in days, and in discipline.
Diluent selection follows the logic in the bacteriostatic water guide: preserved water where a vial will be entered repeatedly, plain sterile water where the preparation is finished in one session, and either where the solution is split into single-use aliquots at preparation. Aliquoting is the practice that pays for its minutes. No container is ever thawed twice, so freeze-thaw damage, which accumulates invisibly, never accumulates on anything.
The arithmetic is the same as for any lyophilized compound. A 10 mg vial brought into 2 mL of diluent holds 10 mg ÷ 2 mL = 5 mg/mL, and the vial concentration calculator covers other vial sizes and volumes. Both the tool and this page describe laboratory measurement only.
Swirl, never shake. An amphiphilic peptide aggregates at the air-water interface, foam is nothing except interface, and aggregate does not redissolve. Dilute solutions lose material a second way: a lipidated peptide adsorbs to glass and to some plastics, and at low concentration that loss surfaces as an inexplicably weak result rather than anything visible. Where a protocol runs dilute, the container material belongs in the method notes.
What the certificate has to prove
A vial's label is a claim; the certificate of analysis is the evidence. For retatrutide the certificate carries more weight than usual, because no pharmacopoeia publishes a monograph for the compound. There is no compendial standard a supplier can point to, so the document stands entirely on the methods it names and the numbers it reports, and it should be read that way.
| Method | What it establishes | What it cannot tell you |
|---|---|---|
| RP-HPLC | Purity as area percent: how much of the dissolved peptide material is a single species | Whether that species is retatrutide at all |
| LC-MS (ESI) | Identity: observed mass against the theoretical mass of the named sequence | How much impurity rides along with it |
| Amino acid analysis or nitrogen determination | Net peptide content: the fraction of gross vial weight that is peptide | Nothing about which peptide it is |
| Karl Fischer titration | Residual water in the lyophilizate | Rarely reported on research certificates; its absence is worth noticing |
The distinction that trips buyers is purity against content. Ninety-nine percent purity means the peptide fraction is one clean species. It does not mean a 10 mg vial contains 10 mg of peptide: bound water and the trifluoroacetate counterion left over from synthesis are part of the gross weight, and a concentration calculated straight from the label without a content figure runs systematically high. A certificate worth relying on reports both numbers, names the method behind each, and carries a lot identifier matching the vial in hand. What that looks like in practice is set out in the quality standard.
The record that follows the vial
Storage that is not documented cannot be defended later. The record for a retatrutide lot starts at receipt: date, lot identifier, certificate filed, condition on arrival noted. Whether the cold pack was still cold matters less than people expect for a dry solid, and it is still worth a line. From there the vial's history is a short list: where it is held, at what temperature, and when the seal was first broken.
A prepared solution inherits and extends that record with the diluent and its lot, the volume added, the resulting concentration, the date, and the initials of whoever made it. Aliquots carry the parent solution's identifier. None of this is bureaucracy for its own sake. When a result comes out wrong, the first question is whether the material was what the protocol assumed, and a record that answers in a minute is the difference between troubleshooting an experiment and repeating a study.
One convention borrowed from formal stability work is worth adopting even in an informal setting: a dated shelf life belongs only to material that has an actual stability study behind it, run on that formulation in that container. Everything else gets a conservative working window and a discard date written on the vial. An undated container is not a mystery to be solved; it is waste.
Regulatory status
Retatrutide is an agonist of the GIP, GLP-1, and glucagon receptors, in clinical development by Eli Lilly. No regulatory agency had approved a medicine containing it as of the verification date below. There is no prescription product, no generic, and no lawful compounded version. Unlike tirzepatide, retatrutide never had a shortage-era compounding window, because there has never been an approved product to be short of.
Programme status, stated without the trial results themselves: phase 2 results in adults with obesity were published in 2023, and the phase 3 TRIUMPH programme announced topline primary readouts in May 2026 for TRIUMPH-1 and in July 2026 for TRIUMPH-2 and TRIUMPH-3. The developer has said it plans to file for United States licensure in the first quarter of 2027. Until an approval exists, material in circulation outside the trial system is either investigational drug supply, which is not for sale, or research-grade chemical, which is not for people.
Status verified 25 August 2026.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Common questions
Does lyophilized retatrutide have to be kept frozen?
Can retatrutide go in a frost-free freezer?
How long does a prepared retatrutide solution last?
What is LY3437943 on my certificate of analysis?
Why is the peptide content lower than the purity?
Is retatrutide available as an approved medicine?
Sources
- Coskun et al., Cell Metabolism, 2022. Preclinical characterization of LY3437943 as a single-peptide GIP, GLP-1, and glucagon receptor agonist; supports the identity and structural description.
- Jastreboff et al., New England Journal of Medicine, 2023. Phase 2 trial of retatrutide in adults with obesity; cited for programme status and its date only, not for its results.
- Eli Lilly TRIUMPH phase 3 announcements, May and July 2026. Topline readout dates for TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3, and the stated plan to file a United States licensing application in the first quarter of 2027.
- ICH Q1A(R2) stability guidance. Basis for the position that a dated shelf life requires a formal stability study on the specific formulation, container, and conditions.